. 2021 Sep 16;23(9):e27576. doi: 10.2196/27576

Table 4.

Multivariate analysis of factors associated with nonadherence.

Characteristics			Odds ratio (95% CI)		P value
Diagnosis year (per year)			0.88 (0.81-0.94)		<.001
Age (years)						<.001
	50-70 vs ≤50	1.08 (0.88-1.31)		.45
	>70 vs ≤50	2.85 (2.19-3.70)		<.001
Educational level (high school or higher vs middle school or lower)			0.76 (0.64-0.91)		.002
Menopausal status (post vs pre)			1.01 (0.72-1.41)		.96
Family history of breast cancer (yes vs no)			0.70 (0.48-1.00)		.05
Axillary surgery (ALND^a vs SLNB^b)			0.72 (0.55-0.96)		.03
Tumor size (>2 cm vs ≤2 cm)			0.83 (0.62-1.09)		.18
Lymph node status (positive vs negative)			1.40 (1.04-1.88)		.03
Pathological subtype (Non-IDC^c vs IDC)			0.77 (0.58-1.02)		.07
Tumor grade						.15
	III versus I or II	1.19 (0.97-1.45)		.10
	Unknown versus I or II	1.36 (0.84-2.20)		.21
PR^d status (positive vs negative)			0.86 (0.66-1.12)		.28
HER2^e status (positive vs negative)			2.04 (1.34-3.10)		.001
Ki-67 index (≥14% vs <14%)			0.96 (0.73-1.26)		.75
Molecular subtype						<.001
	Luminal-B like (HER2 negative) versus Luminal-A like	1.83 (1.29-2.59)		.001
	Luminal-B like (HER2 positive) versus Luminal-A like	1.60 (1.16-2.21)		.005
	HER2 positive versus Luminal-A like	N/A^f		N/A
	Triple negative versus Luminal-A like	2.11 (1.41-3.14)		<.001
TNM^g stage						.02
	Stage II versus stage I	1.35 (1.08-1.69)		.008
	Stage III versus stage I	1.57 (1.09-2.25)		.01
Group according to app use						.02
	App nonused cohort versus Pre-App cohort	0.96 (0.70-1.29)		.77
	App used cohort versus Pre-App cohort	0.61 (0.43-0.87)		.007

^aALND: axillary lymph node dissection.

^bSLNB: sentinel lymph node biopsy.

^cIDC: invasive ductal carcinoma.

^dPR: progesterone receptor.

^eHER2: human epidermal growth factor receptor 2.

^fN/A: not applicable.

^gTNM: tumor, lymph node, and metastasis.